KRAS and cancer: However, the use of ERK MAPK inhibitors for the treatment of PDAC and other KRAS-mutant cancers has been challenging owing to on-target toxicity, acquired resistance, and loss of ERK-dependent negative feedback loops, which ultimately cause reactivation of ERK signaling through RTKs and WT KRAS (74, 75).